Bipolar disorder and comorbid alcoholism

Prevalence rate and treatment considerations

Mark A Frye, Ihsan M. Salloum

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Classic Kraepelian observations and contemporary epidemiological studies have noted a high prevalence rate between bipolar disorder and alcoholism. The extent to which these two illnesses are comorbid (i.e., two distinct disease processes each with an independent course of illness), genetically linked, or different phenotypic expressions of bipolar illness itself continues to be investigated. It is increasingly clear that co-occurring alcohol abuse or dependence in bipolar disorder phenomenologically changes the illness presentation with higher rates of mixed or dysphoric mania, rapid cycling, increased symptom severity, and higher levels of novelty seeking, suicidality, aggressivity, and impulsivity. It is very encouraging that interest and efforts at evaluating pharmacotherapeutic compounds has substantially increased over the past few years in this difficult-to-treat patient population. This article will review the clinical studies that have evaluated the effectiveness of conventional mood stabilizers (lithium, carbamazepine, divalproex, and atypical antipsychotics) in the treatment of alcohol withdrawal and relapse prevention in patients with alcoholism and in the treatment of bipolar disorder with comorbid alcoholism. A number of add-on, adjunctive medications, such as naltrexone, acamprosate, topiramate, and the atypical antipsychotics quetiapine and clozapine, may be candidates for further testing.

Original languageEnglish (US)
Pages (from-to)677-685
Number of pages9
JournalBipolar Disorders
Volume8
Issue number6
DOIs
StatePublished - Dec 2006

Fingerprint

Bipolar Disorder
Alcoholism
Antipsychotic Agents
Therapeutics
Naltrexone
Impulsive Behavior
Clozapine
Carbamazepine
Valproic Acid
Secondary Prevention
Lithium
Epidemiologic Studies
Alcohols
Population

Keywords

  • Alcohol
  • Antipsychotic
  • Bipolar
  • Comorbidity
  • Mood stabilizer

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Cite this

Bipolar disorder and comorbid alcoholism : Prevalence rate and treatment considerations. / Frye, Mark A; Salloum, Ihsan M.

In: Bipolar Disorders, Vol. 8, No. 6, 12.2006, p. 677-685.

Research output: Contribution to journalArticle

@article{27faef34be0740c997590b36e08cf152,
title = "Bipolar disorder and comorbid alcoholism: Prevalence rate and treatment considerations",
abstract = "Classic Kraepelian observations and contemporary epidemiological studies have noted a high prevalence rate between bipolar disorder and alcoholism. The extent to which these two illnesses are comorbid (i.e., two distinct disease processes each with an independent course of illness), genetically linked, or different phenotypic expressions of bipolar illness itself continues to be investigated. It is increasingly clear that co-occurring alcohol abuse or dependence in bipolar disorder phenomenologically changes the illness presentation with higher rates of mixed or dysphoric mania, rapid cycling, increased symptom severity, and higher levels of novelty seeking, suicidality, aggressivity, and impulsivity. It is very encouraging that interest and efforts at evaluating pharmacotherapeutic compounds has substantially increased over the past few years in this difficult-to-treat patient population. This article will review the clinical studies that have evaluated the effectiveness of conventional mood stabilizers (lithium, carbamazepine, divalproex, and atypical antipsychotics) in the treatment of alcohol withdrawal and relapse prevention in patients with alcoholism and in the treatment of bipolar disorder with comorbid alcoholism. A number of add-on, adjunctive medications, such as naltrexone, acamprosate, topiramate, and the atypical antipsychotics quetiapine and clozapine, may be candidates for further testing.",
keywords = "Alcohol, Antipsychotic, Bipolar, Comorbidity, Mood stabilizer",
author = "Frye, {Mark A} and Salloum, {Ihsan M.}",
year = "2006",
month = "12",
doi = "10.1111/j.1399-5618.2006.00370.x",
language = "English (US)",
volume = "8",
pages = "677--685",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Blackwell Munksgaard",
number = "6",

}

TY - JOUR

T1 - Bipolar disorder and comorbid alcoholism

T2 - Prevalence rate and treatment considerations

AU - Frye, Mark A

AU - Salloum, Ihsan M.

PY - 2006/12

Y1 - 2006/12

N2 - Classic Kraepelian observations and contemporary epidemiological studies have noted a high prevalence rate between bipolar disorder and alcoholism. The extent to which these two illnesses are comorbid (i.e., two distinct disease processes each with an independent course of illness), genetically linked, or different phenotypic expressions of bipolar illness itself continues to be investigated. It is increasingly clear that co-occurring alcohol abuse or dependence in bipolar disorder phenomenologically changes the illness presentation with higher rates of mixed or dysphoric mania, rapid cycling, increased symptom severity, and higher levels of novelty seeking, suicidality, aggressivity, and impulsivity. It is very encouraging that interest and efforts at evaluating pharmacotherapeutic compounds has substantially increased over the past few years in this difficult-to-treat patient population. This article will review the clinical studies that have evaluated the effectiveness of conventional mood stabilizers (lithium, carbamazepine, divalproex, and atypical antipsychotics) in the treatment of alcohol withdrawal and relapse prevention in patients with alcoholism and in the treatment of bipolar disorder with comorbid alcoholism. A number of add-on, adjunctive medications, such as naltrexone, acamprosate, topiramate, and the atypical antipsychotics quetiapine and clozapine, may be candidates for further testing.

AB - Classic Kraepelian observations and contemporary epidemiological studies have noted a high prevalence rate between bipolar disorder and alcoholism. The extent to which these two illnesses are comorbid (i.e., two distinct disease processes each with an independent course of illness), genetically linked, or different phenotypic expressions of bipolar illness itself continues to be investigated. It is increasingly clear that co-occurring alcohol abuse or dependence in bipolar disorder phenomenologically changes the illness presentation with higher rates of mixed or dysphoric mania, rapid cycling, increased symptom severity, and higher levels of novelty seeking, suicidality, aggressivity, and impulsivity. It is very encouraging that interest and efforts at evaluating pharmacotherapeutic compounds has substantially increased over the past few years in this difficult-to-treat patient population. This article will review the clinical studies that have evaluated the effectiveness of conventional mood stabilizers (lithium, carbamazepine, divalproex, and atypical antipsychotics) in the treatment of alcohol withdrawal and relapse prevention in patients with alcoholism and in the treatment of bipolar disorder with comorbid alcoholism. A number of add-on, adjunctive medications, such as naltrexone, acamprosate, topiramate, and the atypical antipsychotics quetiapine and clozapine, may be candidates for further testing.

KW - Alcohol

KW - Antipsychotic

KW - Bipolar

KW - Comorbidity

KW - Mood stabilizer

UR - http://www.scopus.com/inward/record.url?scp=34248558680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248558680&partnerID=8YFLogxK

U2 - 10.1111/j.1399-5618.2006.00370.x

DO - 10.1111/j.1399-5618.2006.00370.x

M3 - Article

VL - 8

SP - 677

EP - 685

JO - Bipolar Disorders

JF - Bipolar Disorders

SN - 1398-5647

IS - 6

ER -